Rights and permissions
About this article
Cite this article
Bevacizumab gets thumbs down from NICE for breast cancer. Pharmacoecon. Outcomes News 652, 11 (2012). https://doi.org/10.2165/00151234-201206520-00032
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201206520-00032